New shot aims to silence hepatitis b virus for good

NCT ID NCT07630727

Recruiting now Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 5 times

Summary

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been treated and those already on antiviral therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AHB-171 injection
What this could lead to: If successful, this could point toward a functional cure for chronic hepatitis B, where the virus is suppressed to very low or undetectable levels without lifelong medication.
What could go wrong: This is an early Phase 2 trial with only 138 participants, so results may not apply to everyone. The treatment may not achieve lasting viral suppression, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B, CHRONIC (CHB)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AusperBio Investigational Site
RECRUITING

Beijing, Beijing Municipality, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Chongqing, Chongqing Municipality, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Xiamen, Fujian, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Guangzhou, Guangdong, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Nanning, Guangxi, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Zhengzhou, Henan, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Changzhou, Jiangsu, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Jilin City, Jilin, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Chengdu, Sichuang, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Hangzhou, Zhejiang, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.